Dr Robert Lanza, Chief Scientific Officer of Ocata Therapeutics to Deliver Opening Address at the Massachusetts State Science...

Ocata Therapeutics, Inc. (“Ocata” or “the Company”; NASDAQ: OCAT), a leader in the field of Regenerative Ophthalmology™, today announced that its chief scientific officer, Robert Lanza, M.D., will be delivering the opening address to the judges and students at the Massachusetts State Science & Engineering Fair (MSSEF) being held at the Massachusetts Institute of Technology, in Cambridge, MA on May 1st, 2015.

“Dr. Lanza’s pioneering research in cell biology and regenerative medicine provides hope for millions of people who may one day benefit from new therapies derived from Bob’s work. Remarkably, this work was first recognized as part of an academic science fair” said Dr. Paul Wotton, president and chief executive officer of Ocata Therapeutics. “Bob is a uniquely talented individual who is passionate about contributing to the community of younger scientists, who may in turn generate the breakthrough inventions of the future”.

The Massachusetts State Science & Engineering Fair, founded in 1949 by the prestigious American Academy of Arts & Sciences, has advanced science literacy and inspired new generations of science of science and engineering leaders for over six decades. Dr. Lanza will also address the students at the Official Opening of 2015 MSSEF, providing inspiration to four hundred of the most talented students with the highest quality projects from across the Commonwealth who will be showcasing their inventions and discoveries. Over 200 distinguished scientists and engineers from business, industry and academia will serve as judges, providing the year-end competition with over $525,000 in scholarships and prizes for students who excel.

About Ocata Therapeutics, Inc.

Ocata Therapeutics, Inc. is a clinical stage biotechnology company focused on the development and commercialization of regenerative ophthalmology therapeutics. Ocata’s most advanced products are in clinical trials for the treatment of Stargardt’s macular degeneration, dry age-related macular degeneration, and myopic macular degeneration. Ocata’s intellectual property portfolio includes pluripotent stem cell platforms – hESC and induced pluripotent stem cell (iPSC) – and other cell therapy research programs. For more information, visit www.ocata.com.

for Ocata Therapeutics, Inc.Investors:Westwicke PartnersJohn Woolford, [e-mail]:Russo PartnersDavid Schull, [e-mail]